Single-study clinical trials (versus two) become the default, speeding up common drug approvals, while vaccines still face tougher scrutiny.

As AI tools steer more healthcare decisions, providers and insurers must target high-value use cases, carefully vet vendors, and lock in governance early.

The Eucalyptus deal deepens global reach as diversification beyond compounded GLP-1s in the US becomes urgent.

After an unusual review rejection, the FDA reverses course—a regulatory whiplash that could raise concerns about regulatory consistency.

The FDA’s plans for broader access of medications could boost convenience, but also raise safety risks and drug costs.

Healthcare and pharma marketers should ramp up social listening and host expert Ask Me Anything sessions to drive engagement without feeling intrusive.

Fraudulent care messages drive stress and confusion, pushing brands to rethink patient communication strategies.

Doctors watch less TV than the average US adult, but favor CTV and on-demand—which are prime time for targeted pharma messaging.

India’s GLP-1 rollout next month signals tougher pricing ahead for GLP-1 brands.

Rising FDA enforcement pushes drugmakers to revisit messaging and risk framing.

But as competition intensifies, high traffic isn’t enough—brands must pair visibility with proven product efficacy to convert surging consumer interest into loyalty.

Consumers show cautious interest, but only if tools are clinically validated, transparent, and privacy secure.

Convenience and drug savings will attract some consumers, but Amazon hasn’t yet been able to disrupt the pharmacy space.

The FDA denied an application for its flu vaccine, deepening regulatory doubt and complicating forecasts for vaccine-driven revenue growth.

Doctors must reassert personalized nutrition advice, while food brands should highlight their better-for-you offerings.

Aetna is finally finding its footing, managing medical costs more effectively, even as industry-wide pressures remain.

Its recent Pfizer and TrumpRx partnerships show how pharma companies are betting on D2C distribution and consumer-facing pricing.

Novo’s lawsuit and regulator warnings signal a crackdown on compounded GLP-1s across telehealth.

Big linear TV won’t wow all viewers, but the massive reach can still drive research, provider talks, and care.

Apple isn’t abandoning AI-powered health guidance, but it’s likely holding back until the tech is useful enough to deliver real value.